Compare TPC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPC | DNTH |
|---|---|---|
| Founded | 1894 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.5B |
| IPO Year | 2003 | 2018 |
| Metric | TPC | DNTH |
|---|---|---|
| Price | $78.68 | $94.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $86.00 | ★ $121.00 |
| AVG Volume (30 Days) | 528.0K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | ★ 148.24 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $5,543,039,000.00 | $2,036,000.00 |
| Revenue This Year | $15.37 | N/A |
| Revenue Next Year | $9.99 | $29.48 |
| P/E Ratio | $164.55 | ★ N/A |
| Revenue Growth | ★ 28.11 | N/A |
| 52 Week Low | $43.52 | $18.08 |
| 52 Week High | $100.00 | $102.37 |
| Indicator | TPC | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 52.17 |
| Support Level | $75.61 | $79.27 |
| Resistance Level | $89.46 | $98.70 |
| Average True Range (ATR) | 3.16 | 5.54 |
| MACD | -0.02 | 0.16 |
| Stochastic Oscillator | 48.97 | 45.72 |
Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically it derives key revenue from the United States.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.